# Aisling Capital Management LP: Form 13F holdings

An institutional investment manager in NEW YORK, NY. SEC CIK 1766721.

- Quarter ended: 2026-06-30
- Filed: 2026-08-13
- Reported value: $471.6m
- Positions: 14 (14 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1766721/000176672126000003/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [BRIDGEBIO PHARMA INC (BBIO)](/companies/bbio.md) | COM | $341.8m | 72.5% | 4,589,611 |  | Reduced −500,000 |
| [MONTE ROSA THERAPEUTICS INC (GLUE)](/companies/glue.md) | COM | $37.6m | 8.0% | 1,555,664 |  | Unchanged |
| [SYNDAX PHARMACEUTICALS INC (SNDX)](/companies/sndx.md) | COM | $28.8m | 6.1% | 1,316,806 |  | Unchanged |
| [COMPASS PATHWAYS PLC (CMPS)](/companies/cmps.md) | SPONSORED ADS | $20.3m | 4.3% | 1,432,336 |  | Unchanged |
| [BICARA THERAPEUTICS INC (BCAX)](/companies/bcax.md) | COM | $16.9m | 3.6% | 568,919 |  | Unchanged |
| [BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)](/companies/bbot.md) | COM NEW | $7.8m | 1.6% | 1,018,018 |  | Unchanged |
| [SCHOLAR ROCK HLDG CORP (SRRK)](/companies/srrk.md) | COM | $4.2m | 0.9% | 77,031 |  | Unchanged |
| UROGEN PHARMA LTD | COM | $4.0m | 0.8% | 108,000 |  | Unchanged |
| [BIOMEA FUSION INC (BMEA)](/companies/bmea.md) | COM | $3.0m | 0.6% | 2,048,757 |  | Unchanged |
| [ACLARIS THERAPEUTICS INC (ACRS)](/companies/acrs.md) | COM | $2.3m | 0.5% | 434,455 |  | Unchanged |
| [EUPRAXIA PHARMACEUTICALS INC (EPRX)](/companies/eprx.md) | COM | $2.1m | 0.5% | 325,000 |  | Unchanged |
| [VTV THERAPEUTICS INC (VTVT)](/companies/vtvt.md) | CL A NEW | $1.9m | 0.4% | 50,000 |  | New +50,000 |
| [MARKER THERAPEUTICS INC (MRKR)](/companies/mrkr.md) | COM NEW | $478.3k | 0.1% | 325,370 |  | Unchanged |
| [ONKURE THERAPEUTICS INC (OKUR)](/companies/okur.md) | COM CL A | $404.0k | <0.1% | 88,607 |  | Unchanged |

Source: SEC EDGAR, Form 13F-HR, accession 0001766721-26-000003. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.